São Paulo - Delayed Quote BRL

Dr. Reddy's Laboratories Limited (R1DY34.SA)

Compare
13.63
0.00
(0.00%)
At close: January 27 at 1:23:42 PM GMT-3
Loading Chart for R1DY34.SA
DELL
  • Previous Close 13.63
  • Open 0.00
  • Bid 13.20 x --
  • Ask 13.30 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 16.34
  • Volume 0
  • Avg. Volume 19
  • Market Cap (intraday) 68.436B
  • Beta (5Y Monthly) 0.33
  • PE Ratio (TTM) 18.42
  • EPS (TTM) 0.74
  • Earnings Date Jan 23, 2025
  • Forward Dividend & Yield 0.07 (0.50%)
  • Ex-Dividend Date Jul 12, 2024
  • 1y Target Est --

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

www.drreddys.com

27,048

Full Time Employees

March 31

Fiscal Year Ends

Recent News: R1DY34.SA

View More

Performance Overview: R1DY34.SA

Trailing total returns as of 1/29/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

R1DY34.SA
16.07%
S&P BSE SENSEX
2.36%

1-Year Return

R1DY34.SA
23.51%
S&P BSE SENSEX
8.07%

3-Year Return

R1DY34.SA
25.75%
S&P BSE SENSEX
33.57%

5-Year Return

R1DY34.SA
5.97%
S&P BSE SENSEX
86.50%

Compare To: R1DY34.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: R1DY34.SA

View More

Valuation Measures

Annual
As of 1/27/2025
  • Market Cap

    68.44B

  • Enterprise Value

    67.88B

  • Trailing P/E

    18.53

  • Forward P/E

    16.00

  • PEG Ratio (5yr expected)

    5.16

  • Price/Sales (ttm)

    3.19

  • Price/Book (mrq)

    3.13

  • Enterprise Value/Revenue

    3.18

  • Enterprise Value/EBITDA

    10.79

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.78%

  • Return on Assets (ttm)

    10.40%

  • Return on Equity (ttm)

    19.27%

  • Revenue (ttm)

    299.87B

  • Net Income Avi to Common (ttm)

    53.33B

  • Diluted EPS (ttm)

    0.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    63.07B

  • Total Debt/Equity (mrq)

    15.69%

  • Levered Free Cash Flow (ttm)

    7.55B

Research Analysis: R1DY34.SA

View More

Company Insights: R1DY34.SA

Research Reports: R1DY34.SA

View More

People Also Watch